More Herceptin Biosimilars Move In, But Roche Thinks It Can Stand Its Ground
Executive Summary
Two biosimilar versions of Roche's blockbuster cancer therapy Herceptin reported positive Phase III bioequivalence data at ASCO – setting up for regulatory approvals in Europe, the US and Japan soon.